361 related articles for article (PubMed ID: 19811503)
1. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks.
Brandes JL; Poole Ac; Kallela M; Schreiber CP; MacGregor EA; Silberstein SD; Tobin J; Shaw R
Cephalalgia; 2009 Nov; 29(11):1133-48. PubMed ID: 19811503
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
[TBL] [Abstract][Full Text] [Related]
3. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation.
Silberstein SD; Berner T; Tobin J; Xiang Q; Campbell JC
Headache; 2009 Oct; 49(9):1283-97. PubMed ID: 19751371
[TBL] [Abstract][Full Text] [Related]
4. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine.
Elkind AH; MacGregor EA
Expert Rev Neurother; 2008 May; 8(5):723-36. PubMed ID: 18457529
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
Silberstein SD; Elkind AH; Schreiber C; Keywood C
Neurology; 2004 Jul; 63(2):261-9. PubMed ID: 15277618
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
Diamond ML; Cady RK; Mao L; Biondi DM; Finlayson G; Greenberg SJ; Wright P
Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
[TBL] [Abstract][Full Text] [Related]
7. Frovatriptan in the practice of office-based neurologists/pain therapists: Results of postmarketing surveillance study ALADIN.
Wallasch TM
Adv Ther; 2010 Jan; 27(1):56-62. PubMed ID: 20140543
[TBL] [Abstract][Full Text] [Related]
8. Frovatriptan use in migraineurs with or at high risk of coronary artery disease.
Elkind AH; Satin LZ; Nila A; Keywood C
Headache; 2004 May; 44(5):403-10. PubMed ID: 15147247
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
[TBL] [Abstract][Full Text] [Related]
10. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines.
Coffee AL; Sulak PJ; Hill AJ; Hansen DJ; Kuehl TJ; Clark JW
J Womens Health (Larchmt); 2014 Apr; 23(4):310-7. PubMed ID: 24450487
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.
Wade A; Pawsey S; Whale H; Boyce M; Warrington S
Clin Drug Investig; 2009; 29(5):325-37. PubMed ID: 19366274
[TBL] [Abstract][Full Text] [Related]
12. The Migraine Intervention Score - a tool to improve efficacy of triptans in acute migraine therapy: the ALADIN study.
Göbel H; Heinze A
Int J Clin Pract; 2011 Aug; 65(8):879-86. PubMed ID: 21762313
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies.
MacGregor EA; Pawsey SP; Campbell JC; Hu X
Gend Med; 2010 Apr; 7(2):88-108. PubMed ID: 20435272
[TBL] [Abstract][Full Text] [Related]
14. Tailoring management strategies for the patient with menstrual migraine: focus on prevention and treatment.
Tepper SJ
Headache; 2006 Oct; 46 Suppl 2():S61-8. PubMed ID: 17044843
[TBL] [Abstract][Full Text] [Related]
15. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
16. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
[TBL] [Abstract][Full Text] [Related]
17. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study.
Spierings EL; Keywood C
Pain Med; 2009; 10(4):633-8. PubMed ID: 19453958
[TBL] [Abstract][Full Text] [Related]
18. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine.
Nett R; Mannix LK; Mueller L; Rodgers A; Hustad CM; Skobieranda F; Ramsey KE
Headache; 2008 Sep; 48(8):1194-201. PubMed ID: 18422606
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination.
Cady RK; Banks J; Jones BA; Campbell J
Curr Med Res Opin; 2009 Nov; 25(11):2711-21. PubMed ID: 19778164
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies.
Martin V; Cady R; Mauskop A; Seidman LS; Rodgers A; Hustad CM; Ramsey KE; Skobieranda F
Headache; 2008 Feb; 48(2):226-35. PubMed ID: 18005144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
